C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study - PubMed (original) (raw)
Comparative Study
. 2005 Nov 28;165(21):2473-8.
doi: 10.1001/archinte.165.21.2473.
Affiliations
- PMID: 16314543
- DOI: 10.1001/archinte.165.21.2473
Comparative Study
C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study
Peter W F Wilson et al. Arch Intern Med. 2005.
Abstract
Background: Determination of C-reactive protein (CRP) level has been suggested to improve cardiovascular disease (CVD) risk assessment. This study examines the utility of CRP levels to assess CVD risk in a community setting.
Methods: We performed a prospective observational cohort study on a community population sample. A total of 1949 men and 2497 women without CVD from the Framingham Heart Study underwent CVD risk factor assessment. Initial CVD events during 8 years of follow-up were recorded.
Results: There were 283 major CVD and 160 major coronary heart disease incident events. Age-, sex-, and multivariable-adjusted analyses generally used CRP level categories of less than 1, 1 to 3, and greater than 3 mg/L. In age- and sex-adjusted models, the traditional risk factors and elevated CRP levels indicated increased risk. The age- and sex-adjusted relative risk (RR) and 95% confidence interval (CI) of CRP level greater than 3 mg/L for major CVD was elevated (RR, 1.60; 95% CI, 1.19-2.14), with evidence of attenuation (RR, 1.22; 95% CI, 0.90-1.66) in multivariable models. The C statistic, a measure of the discriminatory capability of the prediction models, was 0.74 for prediction of major CVD with age and CRP level. In multivariable models that included traditional risk factors, the C statistic was 0.78, a value that was unchanged with the addition of CRP to the multivariable model. Similar relations were noted for major coronary heart disease events.
Conclusion: Elevated CRP level provided no further prognostic information beyond traditional office risk factor assessment to predict future major CVD and major coronary heart disease in this population sample.
Comment in
- When is a new prediction marker useful? A consideration of lipoprotein-associated phospholipase A2 and C-reactive protein for stroke risk.
Greenland P, O'Malley PG. Greenland P, et al. Arch Intern Med. 2005 Nov 28;165(21):2454-6. doi: 10.1001/archinte.165.21.2454. Arch Intern Med. 2005. PMID: 16314539 No abstract available. - C-reactive protein and cardiovascular risk in the Framingham Study.
Ridker P, Rifai N, Koenig W, Blumenthal RS. Ridker P, et al. Arch Intern Med. 2006 Jun 26;166(12):1327-8; author reply 1328. doi: 10.1001/archinte.166.12.1327-b. Arch Intern Med. 2006. PMID: 16801524 No abstract available.
Similar articles
- C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study.
Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB Sr, Wilson PW. Rutter MK, et al. Circulation. 2004 Jul 27;110(4):380-5. doi: 10.1161/01.CIR.0000136581.59584.0E. Epub 2004 Jul 19. Circulation. 2004. PMID: 15262834 - C-reactive protein, insulin resistance and risk of cardiovascular disease: a population-based study.
Jeppesen J, Hansen TW, Olsen MH, Rasmussen S, Ibsen H, Torp-Pedersen C, Hildebrandt PR, Madsbad S. Jeppesen J, et al. Eur J Cardiovasc Prev Rehabil. 2008 Oct;15(5):594-8. doi: 10.1097/HJR.0b013e328308bb8b. Eur J Cardiovasc Prev Rehabil. 2008. PMID: 18753952 - Utility of C-reactive protein for cardiovascular risk stratification across three age groups in subjects without existing cardiovascular diseases.
Hamer M, Chida Y, Stamatakis E. Hamer M, et al. Am J Cardiol. 2009 Aug 15;104(4):538-42. doi: 10.1016/j.amjcard.2009.04.020. Epub 2009 Jun 18. Am J Cardiol. 2009. PMID: 19660608 - Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander?
Nordestgaard BG, Zacho J. Nordestgaard BG, et al. Nutr Metab Cardiovasc Dis. 2009 Oct;19(8):521-4. doi: 10.1016/j.numecd.2009.07.005. Epub 2009 Aug 19. Nutr Metab Cardiovasc Dis. 2009. PMID: 19695857 Review. - Screening for heart disease: C-reactive protein versus coronary artery calcium.
Patel AA, Budoff MJ. Patel AA, et al. Expert Rev Cardiovasc Ther. 2010 Jan;8(1):125-31. doi: 10.1586/erc.09.166. Expert Rev Cardiovasc Ther. 2010. PMID: 20014938 Review.
Cited by
- 2024 Guidelines of the Taiwan Society of Cardiology on the Primary Prevention of Atherosclerotic Cardiovascular Disease --- Part I.
Chao TH, Lin TH, Cheng CI, Wu YW, Ueng KC, Wu YJ, Lin WW, Leu HB, Cheng HM, Huang CC, Wu CC, Lin CF, Chang WT, Pan WH, Chen PR, Ting KH, Su CH, Chu CS, Chien KL, Yen HW, Wang YC, Su TC, Liu PY, Chang HY, Chen PW, Juang JJ, Lu YW, Lin PL, Wang CP, Ko YS, Chiang CE, Hou CJ, Wang TD, Lin YH, Huang PH, Chen WJ. Chao TH, et al. Acta Cardiol Sin. 2024 Sep;40(5):479-543. doi: 10.6515/ACS.202409_40(5).20240724A. Acta Cardiol Sin. 2024. PMID: 39308649 Free PMC article. - The impact of blood MCP-1 levels on Alzheimer's disease with genetic variation of UNC5C and NAV3 loci.
Huang J, Wang Y, Stein TD, Ang TFA, Zhu Y, Tao Q, Lunetta KL, Mez J, Au R, Farrer LA, Qiu WQ, Zhang X. Huang J, et al. Res Sq [Preprint]. 2023 Sep 28:rs.3.rs-3376348. doi: 10.21203/rs.3.rs-3376348/v1. Res Sq. 2023. PMID: 37841863 Free PMC article. Preprint. - Predictive Utility of Irritability "In Context": Proof-of-Principle for an Early Childhood Mental Health Risk Calculator.
Wakschlag LS, MacNeill LA, Pool LR, Smith JD, Adam H, Barch DM, Norton ES, Rogers CE, Ahuvia I, Smyser CD, Luby JL, Allen NB. Wakschlag LS, et al. J Clin Child Adolesc Psychol. 2024 Mar-Apr;53(2):231-245. doi: 10.1080/15374416.2023.2188553. Epub 2023 Mar 28. J Clin Child Adolesc Psychol. 2024. PMID: 36975800 - The impact of increasing levels of blood C-reactive protein on the inflammatory loci SPI1 and CD33 in Alzheimer's disease.
Huang J, Tao Q, Ang TFA, Farrell J, Zhu C, Wang Y, Stein TD, Lunetta KL, Massaro J, Mez J, Au R, Farrer LA, Qiu WQ, Zhang X; Alzheimer’s Disease Neuroimaging Initiative. Huang J, et al. Transl Psychiatry. 2022 Dec 22;12(1):523. doi: 10.1038/s41398-022-02281-6. Transl Psychiatry. 2022. PMID: 36550123 Free PMC article. - Blood levels of MCP-1 modulate the genetic risks of Alzheimer's disease mediated by HLA-DRB1 and APOE for Alzheimer's disease.
Huang J, Stein TD, Wang Y, Ang TFA, Tao Q, Lunetta KL, Massaro J, Akhter-Khan SC, Mez J, Au R, Farrer LA, Zhang X, Qiu WQ; Alzheimer's Disease Neuroimaging Initiative. Huang J, et al. Alzheimers Dement. 2023 May;19(5):1925-1937. doi: 10.1002/alz.12851. Epub 2022 Nov 17. Alzheimers Dement. 2023. PMID: 36396603 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous